OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
37291057

Hancom Lifecare Inc

Medical Equipment, Supplies & DistributionVerified

Capital Structure and Liquidity Hancom Lifecare Inc maintains a strong liquidity position, with cash and equivalents amounting to KRW 51.33 billion, representing 25.2% of total assets. The company's current ratio of 1.65 indicates a solid ability to meet short-term obligations. Despite a negative net income of KRW 7.73 billion, the firm generated positive operating cash flow of KRW 22.68 billion, suggesting operational resilience. ### Profitability and Returns The company's profitability is underperforming relative to industry norms. Return on equity (ROE) is -6.08%, and return on assets (ROA) is -3.79%, both significantly below the industry median for Medical Equipment, Supplies & Distribution. Gross profit of KRW 21.41 billion represents 23.3% of revenue, but this is offset by operating losses of KRW 1.25 billion. The negative operating income and net loss highlight operational inefficiencies or pricing pressures. ### Segments and Geographic Exposure The company's revenue is not disclosed by segment or geography, but it operates in a niche market with products tailored for industrial, military, and emergency use. Given the nature of its products, it is likely exposed to government and institutional buyers, which may limit revenue diversification. The absence of segment data prevents a detailed assessment of revenue concentration. ### Growth Trajectory Hancom Lifecare Inc reported revenue of KRW 92.09 billion in the latest period, but the company is currently operating at a net loss. Without disclosed revenue growth rates or forward-looking guidance, it is difficult to assess the trajectory of future performance. The company's capital expenditures of KRW 5.93 billion suggest ongoing investment in production capacity, but the negative free cash flow of KRW 8.81 billion indicates that these investments are not yet generating returns. ### Risk Factors The company faces moderate liquidity risk due to its negative net income and operating losses, but its strong cash position mitigates this risk. There are no immediate dilution risks, as shares outstanding remain unchanged between basic and diluted measures. The absence of long-term debt (KRW 419.59 million) reduces financial leverage risk. However, the company's profitability challenges and reliance on niche markets could expose it to demand volatility. ### Recent Events No recent filings or transcripts were identified that would indicate material changes in the company's operations or strategy. The lack of disclosed events suggests a stable but underperforming business environment.

30-day price · 372910-90.00 (-3.8%)
Low$2205.00High$3030.00Close$2275.00As of21 May, 00:00 UTC
Profile
CompanyHancom Lifecare Inc
Ticker372910.KS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Hancom Lifecare Inc is a Korea-based company engaged in the manufacture of air respirators, gas masks, and special-purpose clothing, primarily serving domestic and foreign markets.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Medical Equipment, Supplies & Distribution industry, with a confidence level of 0.92.

### Capital Structure and Liquidity Hancom Lifecare Inc maintains a strong liquidity position, with cash and equivalents amounting to KRW 51.33 billion, representing 25.2% of total assets. The company's current ratio of 1.65 indicates a solid ability to meet short-term obligations. Despite a negative net income of KRW 7.73 billion, the firm generated positive operating cash flow of KRW 22.68 billion, suggesting operational resilience. ### Profitability and Returns The company's profitability is underperforming relative to industry norms. Return on equity (ROE) is -6.08%, and return on assets (ROA) is -3.79%, both significantly below the industry median for Medical Equipment, Supplies & Distribution. Gross profit of KRW 21.41 billion represents 23.3% of revenue, but this is offset by operating losses of KRW 1.25 billion. The negative operating income and net loss highlight operational inefficiencies or pricing pressures. ### Segments and Geographic Exposure The company's revenue is not disclosed by segment or geography, but it operates in a niche market with products tailored for industrial, military, and emergency use. Given the nature of its products, it is likely exposed to government and institutional buyers, which may limit revenue diversification. The absence of segment data prevents a detailed assessment of revenue concentration. ### Growth Trajectory Hancom Lifecare Inc reported revenue of KRW 92.09 billion in the latest period, but the company is currently operating at a net loss. Without disclosed revenue growth rates or forward-looking guidance, it is difficult to assess the trajectory of future performance. The company's capital expenditures of KRW 5.93 billion suggest ongoing investment in production capacity, but the negative free cash flow of KRW 8.81 billion indicates that these investments are not yet generating returns. ### Risk Factors The company faces moderate liquidity risk due to its negative net income and operating losses, but its strong cash position mitigates this risk. There are no immediate dilution risks, as shares outstanding remain unchanged between basic and diluted measures. The absence of long-term debt (KRW 419.59 million) reduces financial leverage risk. However, the company's profitability challenges and reliance on niche markets could expose it to demand volatility. ### Recent Events No recent filings or transcripts were identified that would indicate material changes in the company's operations or strategy. The lack of disclosed events suggests a stable but underperforming business environment.
Key takeaways
  • Hancom Lifecare Inc maintains strong liquidity despite operating at a net loss.
  • The company's ROE and ROA are significantly below industry medians, indicating poor profitability.
  • Revenue concentration and segment data are not disclosed, limiting visibility into diversification.
  • Capital expenditures suggest ongoing investment, but free cash flow remains negative.
  • No immediate dilution or liquidity risks are present, but profitability challenges persist.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$92.09B
Gross profit$21.41B
Operating income-$1.25B
Net income-$7.73B
R&D
SG&A
D&A
SBC
Operating cash flow$22.68B
CapEx-$5.93B
Free cash flow-$8.81B
Total assets$203.63B
Total liabilities$76.61B
Total equity$127.01B
Cash & equivalents$51.33B
Long-term debt$419.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$92.09B-$1.25B-$7.73B-$8.81B
FY-1$104.78B$7.49B$7.37B$8.59B
FY-2$112.78B$1.12B$824.7M$2.60B
FY-3$100.12B-$10.43B$9.20B$10.66B
FY-4$121.14B$4.70B$4.84B$2.58B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$203.63B$127.01B$51.33B
FY-1$198.51B$134.66B$34.37B
FY-2$182.21B$127.56B$15.74B
FY-3$208.03B$127.19B$58.10B
FY-4$214.13B$116.82B$61.53B
PeriodOCFCapExFCFSBC
FY0$22.68B-$5.93B-$8.81B
FY-1$22.27B-$4.35B$8.59B
FY-2-$8.47B-$5.36B$2.60B
FY-3$5.08B-$6.14B$10.66B
FY-4$28.05B-$10.17B$2.58B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$34.78B-$3.64B-$7.38B-$10.25B
FQ-1$23.57B$2.99B$2.30B$2.79B
FQ-2$27.09B$2.84B$100.2M$1.15B
FQ-3$6.64B-$3.44B-$2.74B-$2.50B
FQ-4$31.30B$1.14B$2.61B$2.97B
FQ-5$23.55B$341.5M-$46.0M-$415.6M
FQ-6$36.28B$6.85B$5.19B$5.57B
FQ-7$13.64B-$847.0M-$384.4M$467.6M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$203.63B$127.01B$51.33B
FQ-1$198.98B$134.47B$36.44B
FQ-2$194.80B$132.10B$24.38B
FQ-3$193.91B$131.88B$23.29B
FQ-4$198.51B$134.66B$34.37B
FQ-5$201.70B$132.35B$23.41B
FQ-6$204.83B$132.41B$20.78B
FQ-7$197.16B$127.23B$10.51B
PeriodOCFCapExFCFSBC
FQ0$22.68B-$5.93B-$10.25B
FQ-1$3.54B-$1.70B$2.79B
FQ-2-$9.16B-$1.03B$1.15B
FQ-3-$10.27B-$952.7M-$2.50B
FQ-4$22.27B-$4.35B$2.97B
FQ-5$7.23B-$3.33B-$415.6M
FQ-6$4.05B-$1.67B$5.57B
FQ-7-$7.23B-$603.2M$467.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$127.01B
Net cash$50.91B
Current ratio1.6
Debt/Equity0.0
ROA-3.8%
ROE-6.1%
Cash conversion-2.9%
CapEx/Revenue-6.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric372910Activity
Op margin-1.4%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-8.4%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin23.3%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-6.4%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity0.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:20 UTC#df85f6c1
Market quoteclose KRW 2450.00 · shares 0.03B diluted
no public URL
2026-05-10 00:43 UTC#651ce1d1
Source: analysis-pipeline (hybrid)Generated: 2026-05-12 01:22 UTCJob: fea536d2